Author

Kaisa Lehti

Primary ORCID profile (0000-0001-9110-8719 · 5 papers)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Kaisa LehtiiD5 papers · Norwegian University of Science and Technology

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Harri Sihto· 1 shared Heikki Joensuu· 1 shared Isabel Burghardt· 1 shared Juha Jääskeläinen· 1 shared Maija Hyvönen· 1 shared Michael Weller· 1 shared Olli Tynninen· 1 shared Pauliina Filppu· 1 shared

Activity by Year

2018-2018 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Harri Sihto

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Vulnerability of invasive glioma cells to lysosomal membrane instabilization

Vadim Le Joncour, Maija Hyvönen, Pauliina Filppu, Pauliina S. Turunen, Harri Sihto, Isabel Burghardt, Heikki Joensuu, Olli Tynninen, Juha Jääskeläinen, Michael Weller, Kaisa Lehti, Pirjo Laakkonen

This paper identifies MDGI as a biomarker for invasive glioma and shows that targeting lysosomal membrane permeabilization with clemastine reduces tumor viability and prolongs survival in preclinical models.

bioRxiv · Mar 5, 2018 · PreprintCancer Biology